Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lung Deposition of PT010 (Breztri Aerosphere) with 3s vs 10s Breath-Hold
NCT03740373Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Breztri Aerosphere in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Percentage lung deposition following 10 s breath hold at Day 1. Started Sep 2018; status: completed.
02
Drugs
Breztri Aerosphere
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03740373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03740373.